Health Canada Could Reconsider Add-On ALS Treatment
Health Canada will allow AB Science to ask for reconsideration for masitinib, a treatment for amyotrophic lateral sclerosis (ALS).
In an April 3 announcement, AB Science said the reconsideration process “will re-examine, with new assessors, the decision based on information that was included in the original submission.”
Health Canada filed a Notice of Deficiency-Withdrawal for masitinib on Feb. 19. ALS News Today described masitinib as “an oral therapy designed to block enzymes that drive inflammation and nerve death in ALS” and said it’s been considered as an add-on therapy for riluzole, “the only therapy proven to date to slow disease progression and extend survival in people with the neurodegenerative condition.”
RESNA’s May Webinar to Examine Adaptive Video Gaming
The Rehabilitation Engineering and Assistive Technology Society of North America’s (RESNA) next webinar will dive into the world of video gaming.
The May 15 session — Current Trends and Innovations in Adaptive Video Gaming — takes place Wed., May 15, at 12 noon Eastern. Presenter Drew Redepenning — a biomedical engineer, assistive technology practitioner and resident physician — has been working in adaptive video gaming for more than five years. “His primary focus,” RESNA said, “is working with individuals with extremely limited mobility and setting them up with equipment to help them game at a high level.”
Registration for the CEU course is free for RESNA members and $45 for non-members.
